DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Belimumab is an investigational drug.
There have been 45 clinical trials for Belimumab. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2013.
The most common disease conditions in clinical trials are Lupus Erythematosus, Systemic, Glomerulonephritis, Membranous, and Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, Human Genome Sciences Inc., and Human Genome Sciences Inc., a GSK Company.
There are forty US patents protecting this investigational drug and eight hundred and seventy-one international patents.
Recent Clinical Trials for Belimumab
|Belimumab With Rituximab for Primary Membranous Nephropathy||Immune Tolerance Network (ITN)||Phase 2|
|Belimumab With Rituximab for Primary Membranous Nephropathy||National Institute of Allergy and Infectious Diseases (NIAID)||Phase 2|
|Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis||GlaxoSmithKline||Phase 2|
Top disease conditions for Belimumab
Top clinical trial sponsors for Belimumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Belimumab||Start Trial||Compositions and methods for treating or preventing lupus||The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)||Start Trial|
|Belimumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Belimumab||Start Trial||Methods for diagnosing systemic lupus erythematosus||Exagen Diagnostics, Inc. (Vista, CA)||Start Trial|
|Belimumab||Start Trial||Constructs having a SIRP-.alpha. domain or variant thereof||ALX ONCOLOGY INC. (Burlingame, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|